Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CYCS (ImmuneEditome ID:54205)

1. Gene summary of enriched editing regions for CYCS

Gene summary

Gene information	Gene symbol	CYCS
	Gene ID	54205
	GeneSynonyms	CYC\|HCS\|THC4
	GeneCytomap	7p15.3
	GeneType	protein-coding
	GeneDescription	cytochrome c
	GeneModificationdate	20230509
	UniprotID	P99999;G4XXL9;C9JFR7
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr7:25120067-25121929:-	ENST00000305786.5	ENSG00000172115.7	CYCS	UTR3	AluSp,AluSx1,MER3,AluJb,AluSq4	chr7:25120067-25121929:-.alignment

Top

2. Tumor-specific enriched editing regions for CYCS

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr7:25120067-25121929:-	BRCA	EER	3.8317e-04
ENSG00000172115.7,CYCS	BRCA	EAG	4.0961e-04
chr7:25120067-25121929:-	COAD	EER	1.6492e-10
ENSG00000172115.7,CYCS	COAD	EAG	1.8690e-10
chr7:25120067-25121929:-	HNSC	EER	2.1877e-05
ENSG00000172115.7,CYCS	HNSC	EAG	1.6307e-05
chr7:25120067-25121929:-	KIRC	EER	3.6152e-14
ENSG00000172115.7,CYCS	KIRC	EAG	3.6152e-14
chr7:25120067-25121929:-	KIRP	EER	4.2482e-08
ENSG00000172115.7,CYCS	KIRP	EAG	4.2482e-08
chr7:25120067-25121929:-	STAD	EER	2.4610e-06
ENSG00000172115.7,CYCS	STAD	EAG	2.4610e-06
chr7:25120067-25121929:-	THCA	EER	6.9345e-12
ENSG00000172115.7,CYCS	THCA	EAG	6.9345e-12

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

StageType

AnovaP

Boxplot

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for CYCS

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr7:25120067-25121929:-

KICH

EER

ENSG00000228343,RP11-1148L6.5

-0.5911

2.3602e-02

3.0331e-05

-0.4998

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_TGF_BETA_SIGNALING

chr7:25120067-25121929:-

KICH

EER

ENSG00000092330,TINF2

-0.5573

2.9215e-02

1.5891e-04

-0.4583

B_cells_naive

GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING

chr7:25120067-25121929:-

KICH

EER

ENSG00000197077,KIAA1671

-0.5507

2.9696e-02

3.2872e-04

-0.4382

Macrophages_M0

GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY

chr7:25120067-25121929:-

KICH

EER

ENSG00000078304,PPP2R5C

-0.5478

3.9391e-02

3.5587e-04

-0.4359

PPP2R5C

B_cells_naive

GSVA_HALLMARK_PROTEIN_SECRETION

chr7:25120067-25121929:-

KICH

EER

ENSG00000171466,ZNF562

-0.5416

3.9494e-02

2.0800e-04

-0.4510

Dendritic_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

chr7:25120067-25121929:-

KICH

EER

ENSG00000150961,SEC24D

-0.5403

4.1804e-02

6.1732e-05

-0.4827

Monocytes

GSVA_HALLMARK_ANDROGEN_RESPONSE

chr7:25120067-25121929:-

KICH

EER

ENSG00000277161,PIGW

-0.5303

4.2150e-02

1.0365e-03

-0.4036

B_cells_naive

GSVA_HALLMARK_PROTEIN_SECRETION

chr7:25120067-25121929:-

KICH

EER

ENSG00000109971,HSPA8

-0.5300

4.2150e-02

2.4721e-05

-0.5046

HSPA8

Neutrophils

GSVA_HALLMARK_PROTEIN_SECRETION

chr7:25120067-25121929:-

KICH

EER

ENSG00000134001,EIF2S1

-0.5299

4.2345e-02

9.2321e-04

-0.4073

B_cells_naive

GSVA_HALLMARK_MTORC1_SIGNALING

chr7:25120067-25121929:-

KICH

EER

ENSG00000102218,RP2

-0.5324

4.2872e-02

9.9504e-04

-0.4049

B_cells_naive

GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING

More results

Top

4. Enriched editing regions and immune related splicing for CYCS

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr7:25120067-25121929:-

PCPG

EER

ENSG00000166169.12

chr10

101587245:101587406:101587821:101587930

-0.2854

2.1393e-02

4.8168e-06

-0.4053

POLL

Mast_cells_activated

GSVA_HALLMARK_MYC_TARGETS_V1

ENSG00000172115.7,CYCS

PCPG

EAG

ENSG00000166169.12

chr10

101587245:101587406:101587821:101587930

-0.2854

1.9844e-02

4.8168e-06

-0.4053

AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;YWHAG;ZNF184

POLL

Mast_cells_activated

GSVA_HALLMARK_MYC_TARGETS_V1

More results

Top

5. Enriched editing regions and immune infiltration for CYCS

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr7:25120067-25121929:-	ACC	EER	Neutrophils	3.4587e-04	0.5705
ENSG00000172115.7,CYCS	ACC	EAG	Neutrophils	3.4587e-04	0.5705
chr7:25120067-25121929:-	CESC	EER	Macrophages_M2	1.7363e-02	-0.2502
ENSG00000172115.7,CYCS	CESC	EAG	Macrophages_M2	1.7363e-02	-0.2502
chr7:25120067-25121929:-	COAD	EER	Plasma_cells	3.0636e-03	-0.2252
ENSG00000172115.7,CYCS	COAD	EAG	Plasma_cells	3.3286e-03	-0.2233
chr7:25120067-25121929:-	ESCA	EER	Mast_cells_activated	4.6900e-02	-0.1726
ENSG00000172115.7,CYCS	ESCA	EAG	Mast_cells_activated	4.6900e-02	-0.1726
chr7:25120067-25121929:-	GBM	EER	Macrophages_M0	1.2589e-04	-0.3004
ENSG00000172115.7,CYCS	GBM	EAG	Macrophages_M0	1.2589e-04	-0.3004
chr7:25120067-25121929:-	HNSC	EER	T_cells_CD4_naive	5.9215e-03	0.1995
ENSG00000172115.7,CYCS	HNSC	EAG	T_cells_CD4_naive	7.5025e-03	0.1934
chr7:25120067-25121929:-	KICH	EER	T_cells_CD4_memory_activated	9.2330e-07	0.5730
ENSG00000172115.7,CYCS	KICH	EAG	T_cells_CD4_memory_activated	9.2330e-07	0.5730
chr7:25120067-25121929:-	KIRC	EER	T_cells_regulatory_(Tregs)	8.9624e-03	0.1724
ENSG00000172115.7,CYCS	KIRC	EAG	T_cells_regulatory_(Tregs)	8.9624e-03	0.1724
chr7:25120067-25121929:-	KIRP	EER	T_cells_CD4_memory_resting	1.4622e-02	-0.1707
ENSG00000172115.7,CYCS	KIRP	EAG	T_cells_CD4_memory_resting	1.4622e-02	-0.1707
chr7:25120067-25121929:-	LGG	EER	Macrophages_M0	1.1844e-03	-0.1429
ENSG00000172115.7,CYCS	LGG	EAG	Macrophages_M0	1.1844e-03	-0.1429
chr7:25120067-25121929:-	LIHC	EER	T_cells_CD4_naive	1.5338e-02	0.2419
ENSG00000172115.7,CYCS	LIHC	EAG	T_cells_CD4_naive	1.5338e-02	0.2419
chr7:25120067-25121929:-	LUAD	EER	Neutrophils	4.7652e-04	0.2855
ENSG00000172115.7,CYCS	LUAD	EAG	Neutrophils	4.7652e-04	0.2855
chr7:25120067-25121929:-	LUSC	EER	Macrophages_M0	3.0350e-02	-0.1481
ENSG00000172115.7,CYCS	LUSC	EAG	Macrophages_M0	3.0350e-02	-0.1481
chr7:25120067-25121929:-	OV	EER	Dendritic_cells_resting	4.6651e-03	-0.2061
ENSG00000172115.7,CYCS	OV	EAG	Dendritic_cells_resting	4.6651e-03	-0.2061
chr7:25120067-25121929:-	PCPG	EER	T_cells_CD8	3.6330e-02	0.1765
ENSG00000172115.7,CYCS	PCPG	EAG	T_cells_CD8	3.6330e-02	0.1765
chr7:25120067-25121929:-	PRAD	EER	T_cells_gamma_delta	4.7360e-03	0.1531
ENSG00000172115.7,CYCS	PRAD	EAG	T_cells_gamma_delta	4.7360e-03	0.1531
chr7:25120067-25121929:-	READ	EER	Mast_cells_activated	2.8652e-02	0.2598
ENSG00000172115.7,CYCS	READ	EAG	Mast_cells_activated	2.8652e-02	0.2598
chr7:25120067-25121929:-	SARC	EER	T_cells_CD4_memory_resting	2.6515e-03	-0.2731
ENSG00000172115.7,CYCS	SARC	EAG	T_cells_CD4_memory_resting	2.6515e-03	-0.2731
chr7:25120067-25121929:-	SKCM	EER	T_cells_gamma_delta	3.4166e-03	0.1541
ENSG00000172115.7,CYCS	SKCM	EAG	T_cells_gamma_delta	3.4166e-03	0.1541
chr7:25120067-25121929:-	STAD	EER	B_cells_naive	3.6450e-05	-0.2399
ENSG00000172115.7,CYCS	STAD	EAG	B_cells_naive	3.6450e-05	-0.2399
chr7:25120067-25121929:-	THCA	EER	Dendritic_cells_resting	2.6458e-03	0.1846
ENSG00000172115.7,CYCS	THCA	EAG	Dendritic_cells_resting	2.6458e-03	0.1846
chr7:25120067-25121929:-	THYM	EER	T_cells_CD4_memory_resting	1.3298e-02	-0.3587
ENSG00000172115.7,CYCS	THYM	EAG	T_cells_CD4_memory_resting	1.3298e-02	-0.3587
chr7:25120067-25121929:-	UCEC	EER	Dendritic_cells_activated	1.9907e-02	0.3077
ENSG00000172115.7,CYCS	UCEC	EAG	Dendritic_cells_activated	1.9907e-02	0.3077
chr7:25120067-25121929:-	UVM	EER	T_cells_regulatory_(Tregs)	2.4631e-02	0.3208
ENSG00000172115.7,CYCS	UVM	EAG	T_cells_regulatory_(Tregs)	2.4631e-02	0.3208

Top

6. Enriched editing regions and immune gene sets for CYCS

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000172115.7,CYCS	ACC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	4.7237e-03	-0.4666
chr7:25120067-25121929:-	ACC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	4.7237e-03	-0.4666
chr7:25120067-25121929:-	BLCA	GSVA_HALLMARK_UV_RESPONSE_UP	EER	6.4567e-03	0.2443
ENSG00000172115.7,CYCS	BLCA	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	6.4567e-03	0.2443
ENSG00000172115.7,CYCS	BRCA	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	7.5591e-05	0.1489
chr7:25120067-25121929:-	BRCA	GSVA_HALLMARK_UV_RESPONSE_UP	EER	8.5840e-05	0.1478
ENSG00000172115.7,CYCS	CESC	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	3.2691e-03	-0.3068
chr7:25120067-25121929:-	CESC	GSVA_HALLMARK_NOTCH_SIGNALING	EER	3.2691e-03	-0.3068
chr7:25120067-25121929:-	ESCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	2.7346e-02	0.1914
ENSG00000172115.7,CYCS	ESCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	2.7346e-02	0.1914
chr7:25120067-25121929:-	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	5.0959e-09	0.4440
ENSG00000172115.7,CYCS	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	5.0959e-09	0.4440
chr7:25120067-25121929:-	HNSC	GSVA_HALLMARK_HYPOXIA	EER	1.3433e-02	0.1795
ENSG00000172115.7,CYCS	HNSC	GSVA_HALLMARK_HYPOXIA	EAG	7.6639e-03	0.1929
ENSG00000172115.7,CYCS	KICH	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	6.4429e-04	-0.4184
chr7:25120067-25121929:-	KICH	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	6.4429e-04	-0.4184
ENSG00000172115.7,CYCS	KIRC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	6.3139e-03	0.1800
chr7:25120067-25121929:-	KIRC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	6.3139e-03	0.1800
ENSG00000172115.7,CYCS	KIRP	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	3.6590e-04	-0.2471
chr7:25120067-25121929:-	KIRP	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	3.6590e-04	-0.2471
chr7:25120067-25121929:-	LGG	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	5.2612e-13	-0.3118
ENSG00000172115.7,CYCS	LGG	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	5.2612e-13	-0.3118
chr7:25120067-25121929:-	LIHC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	2.1770e-02	0.2292
ENSG00000172115.7,CYCS	LIHC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	2.1770e-02	0.2292
chr7:25120067-25121929:-	LUSC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	2.6513e-03	0.2045
ENSG00000172115.7,CYCS	LUSC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	2.6513e-03	0.2045
ENSG00000172115.7,CYCS	MESO	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	2.6246e-02	0.4957
chr7:25120067-25121929:-	MESO	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	2.6246e-02	0.4957
chr7:25120067-25121929:-	OV	GSVA_HALLMARK_UV_RESPONSE_DN	EER	1.9442e-02	-0.1708
ENSG00000172115.7,CYCS	OV	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.9442e-02	-0.1708
chr7:25120067-25121929:-	PAAD	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.6773e-02	0.3368
ENSG00000172115.7,CYCS	PAAD	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	1.6773e-02	0.3368
chr7:25120067-25121929:-	PCPG	GSVA_HALLMARK_DNA_REPAIR	EER	3.5213e-02	0.1775
ENSG00000172115.7,CYCS	PCPG	GSVA_HALLMARK_DNA_REPAIR	EAG	3.5213e-02	0.1775
chr7:25120067-25121929:-	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	3.1024e-06	-0.2502
ENSG00000172115.7,CYCS	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	3.1024e-06	-0.2502
ENSG00000172115.7,CYCS	READ	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	1.0061e-02	-0.3036
chr7:25120067-25121929:-	READ	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.0061e-02	-0.3036
ENSG00000172115.7,CYCS	SARC	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	1.4467e-04	0.3414
chr7:25120067-25121929:-	SARC	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.4467e-04	0.3414
chr7:25120067-25121929:-	SKCM	GSVA_HALLMARK_UV_RESPONSE_UP	EER	4.7256e-05	0.2130
ENSG00000172115.7,CYCS	SKCM	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	4.7256e-05	0.2130
ENSG00000172115.7,CYCS	STAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	2.0967e-03	0.1799
chr7:25120067-25121929:-	STAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	2.0967e-03	0.1799
ENSG00000172115.7,CYCS	TGCT	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	2.4413e-02	0.2358
chr7:25120067-25121929:-	TGCT	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	2.4413e-02	0.2358
ENSG00000172115.7,CYCS	THCA	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	1.4047e-05	0.2643
chr7:25120067-25121929:-	THCA	GSVA_HALLMARK_NOTCH_SIGNALING	EER	1.4047e-05	0.2643
chr7:25120067-25121929:-	UCEC	GSVA_HALLMARK_G2M_CHECKPOINT	EER	3.4166e-02	-0.2811
ENSG00000172115.7,CYCS	UCEC	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	3.4166e-02	-0.2811
ENSG00000172115.7,CYCS	UCS	GSVA_HALLMARK_APICAL_JUNCTION	EAG	9.8829e-04	0.6657
chr7:25120067-25121929:-	UCS	GSVA_HALLMARK_APICAL_JUNCTION	EER	9.8829e-04	0.6657
ENSG00000172115.7,CYCS	UVM	GSVA_HALLMARK_APICAL_SURFACE	EAG	2.6143e-02	0.3176
chr7:25120067-25121929:-	UVM	GSVA_HALLMARK_APICAL_SURFACE	EER	2.6143e-02	0.3176

Top

7. Enriched editing regions and drugs for CYCS

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr7:25120067-25121929:-	ACC	Lapatinib	EER	2.0976e-03	0.5025
ENSG00000172115.7,CYCS	ACC	Lapatinib	EAG	2.0976e-03	0.5025
ENSG00000172115.7,CYCS	BLCA	CGP.60474	EAG	2.7793e-03	-0.2675
chr7:25120067-25121929:-	BLCA	CGP.60474	EER	2.7793e-03	-0.2675
ENSG00000172115.7,CYCS	BRCA	GW843682X	EAG	5.8221e-06	-0.1703
chr7:25120067-25121929:-	BRCA	GW843682X	EER	8.2927e-06	-0.1675
ENSG00000172115.7,CYCS	ESCA	CGP.60474	EAG	6.3499e-04	-0.2925
chr7:25120067-25121929:-	ESCA	CGP.60474	EER	6.3499e-04	-0.2925
chr7:25120067-25121929:-	GBM	BIBW2992	EER	4.9839e-11	-0.4924
ENSG00000172115.7,CYCS	GBM	BIBW2992	EAG	4.9839e-11	-0.4924
ENSG00000172115.7,CYCS	HNSC	CGP.60474	EAG	9.9777e-04	-0.2369
chr7:25120067-25121929:-	HNSC	CGP.60474	EER	1.8280e-03	-0.2253
chr7:25120067-25121929:-	KICH	Gefitinib	EER	1.4413e-03	-0.3930
ENSG00000172115.7,CYCS	KICH	Gefitinib	EAG	1.4413e-03	-0.3930
ENSG00000172115.7,CYCS	KIRC	CGP.60474	EAG	2.6584e-04	-0.2388
chr7:25120067-25121929:-	KIRC	CGP.60474	EER	2.6584e-04	-0.2388
ENSG00000172115.7,CYCS	KIRP	BMS.708163	EAG	1.2332e-05	0.3008
chr7:25120067-25121929:-	KIRP	BMS.708163	EER	1.2332e-05	0.3008
chr7:25120067-25121929:-	LGG	Erlotinib	EER	4.3878e-18	-0.3706
ENSG00000172115.7,CYCS	LGG	Erlotinib	EAG	4.3878e-18	-0.3706
ENSG00000172115.7,CYCS	LIHC	BMS.708163	EAG	1.7148e-02	0.2379
chr7:25120067-25121929:-	LIHC	BMS.708163	EER	1.7148e-02	0.2379
chr7:25120067-25121929:-	LUSC	CCT007093	EER	1.1324e-02	0.1728
ENSG00000172115.7,CYCS	LUSC	CCT007093	EAG	1.1324e-02	0.1728
ENSG00000172115.7,CYCS	MESO	GDC0941	EAG	7.2778e-03	0.5806
chr7:25120067-25121929:-	MESO	GDC0941	EER	7.2778e-03	0.5806
chr7:25120067-25121929:-	OV	JNK.9L	EER	2.4624e-06	0.3367
ENSG00000172115.7,CYCS	OV	JNK.9L	EAG	2.4624e-06	0.3367
ENSG00000172115.7,CYCS	PAAD	CCT007093	EAG	1.4220e-02	0.3447
chr7:25120067-25121929:-	PAAD	CCT007093	EER	1.4220e-02	0.3447
ENSG00000172115.7,CYCS	PCPG	GDC.0449	EAG	1.0105e-03	-0.2740
chr7:25120067-25121929:-	PCPG	GDC.0449	EER	1.0105e-03	-0.2740
chr7:25120067-25121929:-	PRAD	CCT007093	EER	1.8276e-04	0.2019
ENSG00000172115.7,CYCS	PRAD	CCT007093	EAG	1.8276e-04	0.2019
chr7:25120067-25121929:-	READ	Bicalutamide	EER	2.4816e-02	-0.2662
ENSG00000172115.7,CYCS	READ	Bicalutamide	EAG	2.4816e-02	-0.2662
chr7:25120067-25121929:-	SARC	AZD.2281	EER	2.3000e-04	-0.3316
ENSG00000172115.7,CYCS	SARC	AZD.2281	EAG	2.3000e-04	-0.3316
ENSG00000172115.7,CYCS	SKCM	CEP.701	EAG	1.2059e-05	-0.2287
chr7:25120067-25121929:-	SKCM	CEP.701	EER	1.2059e-05	-0.2287
ENSG00000172115.7,CYCS	STAD	ABT.263	EAG	8.3223e-03	0.1550
chr7:25120067-25121929:-	STAD	ABT.263	EER	8.3223e-03	0.1550
ENSG00000172115.7,CYCS	TGCT	JNJ.26854165	EAG	2.2835e-02	-0.2385
chr7:25120067-25121929:-	TGCT	JNJ.26854165	EER	2.2835e-02	-0.2385
ENSG00000172115.7,CYCS	THCA	GNF.2	EAG	4.9489e-06	-0.2774
chr7:25120067-25121929:-	THCA	GNF.2	EER	4.9489e-06	-0.2774
chr7:25120067-25121929:-	UCEC	BX.795	EER	1.8222e-02	0.3118
ENSG00000172115.7,CYCS	UCEC	BX.795	EAG	1.8222e-02	0.3118
ENSG00000172115.7,CYCS	UCS	Lapatinib	EAG	6.5997e-03	-0.5732
chr7:25120067-25121929:-	UCS	Lapatinib	EER	6.5997e-03	-0.5732
ENSG00000172115.7,CYCS	UVM	GDC.0449	EAG	1.1354e-04	-0.5235
chr7:25120067-25121929:-	UVM	GDC.0449	EER	1.1354e-04	-0.5235

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER	ENST	UniprotID	DrugBankID	Drug	DrugType
chr7:25120067-25121929:-	ENST00000305786.5	P99999	DB01017	Minocycline	SmallMoleculeDrug
chr7:25120067-25121929:-	ENST00000305786.5	P99999	DB11638	Artenimol	SmallMoleculeDrug